Vascular Mineralocorticoid Receptors: Linking Risk Factors, Hypertension, and Heart Disease

Hypertension

Volumn 68, Issue 1, 2016, Pages 6-10

  Lother, Achim ^a,b   Hein, Lutz ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPITHELIAL SODIUM CHANNEL; MINERALOCORTICOID RECEPTOR;

ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; EXPERIMENTAL MYOCARDIAL INFARCTION; HEART DISEASE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; BLOOD VESSEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALDOSTERONE; BLOOD VESSELS; HEART DISEASES; HUMANS; HYPERTENSION; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84969916650     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07418     Document Type: Article

References (49)

1. Jia G, Habibi J, Aroor AR, Martinez-Lemus LA, De Marco VG, Ramirez-Perez FI, Sun Z, Hayden MR, Meininger GA, Mueller KB, Jaffe IZ, Sowers JR. Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res. 2016;118:935-943. doi: 10.1161/CIRCRESAHA.115.308269.
2. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013;62:1105-1110. doi: 10.1161/HYPERTENSIONAHA.113.01744.
3. Takatsu M, Nakashima C, Takahashi K, Murase T, Hattori T, Ito H, Murohara T, Nagata K. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension. 2013;62:957-965. doi: 10.1161/HYPERTENSIONAHA.113.02093.
4. Jia G, Habibi J, De Marco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT, Aroor AR, Domeier TL, Zhu Y, Meininger GA, Barrett Mueller K, Jaffe IZ, Sowers JR. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension. 2015;66:1159-1167. doi: 10.1161/HYPERTENSIONAHA.115.06015.
5. De Marco VG, Habibi J, Jia G, Aroor AR, Ramirez-Perez FI, Martinez-Lemus LA, Bender SB, Garro M, Hayden MR, Sun Z, Meininger GA, Manrique C, Whaley-Connell A, Sowers JR. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66:99-107. doi: 10.1161/HYPERTENSIONAHA.115.05674.
6. Schäfer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Lüscher TF, Verrey F, Matter CM. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J. 2013;34:3515-3524. doi: 10.1093/eurheartj/eht095.
7. Wang M, Zhang J, Telljohann R, Jiang L, Wu J, Monticone RE, Kapoor K, Talan M, Lakatta EG. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension. 2012;60:459-466. doi: 10.1161/HYPERTENSIONAHA.112.191270.
8. Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65:252-256. doi: 10.1161/HYPERTENSIONAHA.114.03617.
9. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
10. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. doi: 10.1056/NEJMoa052256.
11. Eschalier R, Rossignol P, Kearney-Schwartz A, Adamopoulos C, Karatzidou K, Fay R, Mandry D, Marie PY, Zannad F. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension. 2014;63:740-746. doi: 10.1161/HYPERTENSIONAHA.113.02419.
12. Roman MJ, Devereux RB. Association of central and peripheral blood pressures with intermediate cardiovascular phenotypes. Hypertension. 2014;63:1148-1153. doi: 10.1161/HYPERTENSIONAHA.114.03361.
13. Kitzman DW, Herrington DM, Brubaker PH, Moore JB, Eggebeen J, Haykowsky MJ. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension. 2013;61:112-119. doi: 10.1161/HYPERTENSIONAHA.111.00163.
14. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessì-Fulgheri P, Sarzani R, Burnett JC, Jr. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015;65:45-53. doi: 10.1161/HYPERTENSIONAHA.114.03936.
15. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078. doi: 10.1161/HYPERTENSIONAHA.111.190223.
16. Catena C, Verheyen N, Pilz S, Kraigher-Krainer E, Tomaschitz A, Sechi LA, Pieske B. Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. Hypertension. 2015;65:1231-1237. doi: 10.1161/HYPERTENSIONAHA.115.05285.
17. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263. doi: 10.1161/HYPERTENSIONAHA.114.04488.
18. Lother A, Moser M, Bode C, Feldman RD, Hein L. Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol. 2015;55:289-312. doi: 10.1146/annurev-pharmtox-010814-124302.
19. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350:256-265. doi: 10.1016/j. mce.2011.06.014.
20. Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jaisser F, Ouvrard-Pascaud A. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension. 2016;67:717-723. doi: 10.1161/HYPERTENSIONAHA.115.06709.
21. Ambroisine ML, Favre J, Oliviero P, Rodriguez C, Gao J, Thuillez C, Samuel JL, Richard V, Delcayre C. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation. 2007;116:2435-2443. doi: 10.1161/CIRCULATIONAHA.107.722009.
22. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18:1429-1433. doi: 10.1038/nm.2891.
23. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosteronesalt to induce vascular stiffness. Hypertension. 2014;63:520-526. doi: 10.1161/HYPERTENSIONAHA.113.01967.
24. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24:2454-2463. doi: 10.1096/fj.09-147926.
25. Mueller KB, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, Hill MA, Jaffe IZ. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension. 2015;66:988-997. doi: 10.1161/HYPERTENSIONAHA.115.06172.
26. Lother A, Fürst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB, Hilgendorf I, Bode C, Moser M, Hein L. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension. 2016;67:130-138. doi: 10.1161/HYPERTENSIONAHA.115.06530.
27. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension. 2014;63:1033-1040. doi: 10.1161/HYPERTENSIONAHA.113.01803.
28. Huby AC, Otvos L, Jr, Belin de Chantemèle EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension. 2016;67:1020-1028. doi: 10.1161/HYPERTENSIONAHA.115.06642.
29. Paar M, Pavenstädt H, Kusche-Vihrog K, Drüppel V, Oberleithner H, Kliche K. Endothelial sodium channels trigger endothelial salt sensitivity with aging. Hypertension. 2014;64:391-396. doi: 10.1161/HYPERTENSIONAHA.114.03348.
30. Pérez FR, Venegas F, González M, Andrés S, Vallejos C, Riquelme G, Sierralta J, Michea L. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension. 2009;53:1000-1007. doi: 10.1161/HYPERTENSIONAHA.108.128520.
31. Jeggle P, Callies C, Tarjus A, Fassot C, Fels J, Oberleithner H, Jaisser F, Kusche-Vihrog K. Epithelial sodium channel stiffens the vascular endothelium in vitro and in Liddle mice. Hypertension. 2013;61:1053-1059. doi: 10.1161/HYPERTENSIONAHA.111.199455.
32. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-543. doi: 10.1161/HYPERTENSIONAHA.109.131110.
33. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161-167. doi: 10.1161/HYPERTENSIONAHA.107.095489.
34. Bender SB, De Marco VG, Padilla J, Jenkins NT, Habibi J, Garro M, Pulakat L, Aroor AR, Jaffe IZ, Sowers JR. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65:1082-1088. doi: 10.1161/HYPERTENSIONAHA.114.04912.
35. Kirsch T, Beese M, Wyss K, Klinge U, Haller H, Haubitz M, Fiebeler A. Aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity by rearrangement of the actin cytoskeleton. Hypertension. 2013;61:501-508. doi: 10.1161/HYPERTENSIONAHA.111.196832.
36. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol. 2014;34:355-364. doi: 10.1161/ATVBAHA.113.302854.
37. Latouche C, Sainte-Marie Y, Steenman M, Castro Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman N, Jaisser F. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology. 2010;151:4467-4476. doi: 10.1210/en.2010-0237.
38. Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T, Mak TW, Fay R, Farman N, Rossignol P, Zannad F, López-Andrés N, Jaisser F. Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension. 2015;66:158-166. doi: 10.1161/HYPERTENSIONAHA.115.05431.
39. Libhaber E, Woodiwiss AJ, Raymond A, Gomes M, Maseko MJ, Sareli P, Norton GR. Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample. Hypertension. 2015;65:1356-1364. doi: 10.1161/HYPERTENSIONAHA.115.05159.
40. Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, Rossignol P, Islas F, Antequera A, Prieto S, Luaces M, Cachofeiro V. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension. 2015;66:961-969. doi: 10.1161/HYPERTENSIONAHA.115.06032.
41. Vergaro G, Prud'homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A, Delcayre C. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 2016;67:606-612. doi: 10.1161/HYPERTENSIONAHA.115.06161.
42. Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015;66:767-775. doi: 10.1161/HYPERTENSIONAHA.115.05876.
43. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58:1008-1013. doi: 10.1161/HYPERTENSIONAHA.111.180497.
44. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691-697. doi: 10.1161/HYPERTENSIONAHA.113.01448.
45. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152. doi: 10.1161/HYPERTENSIONAHA.109.140988.
46. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-2068. doi: 10.1016/S0140-6736(15)00257-3.
47. Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized Prague-15 study. Hypertension. 2016;67:397-403. doi: 10.1161/HYPERTENSIONAHA.115.06526.
48. Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi: 10.1056/NEJMoa1313731.
49. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42. doi: 10.1161/CIRCULATIONAHA.114.013255.